Your browser is no longer supported. Please, upgrade your browser.
Werewolf Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own16.60% Shs Outstand17.75M Perf Week-5.16%
Market Cap441.18M Forward P/E- EPS next Y-1.64 Insider Trans121.81% Shs Float- Perf Month-8.74%
Income- PEG- EPS next Q-0.44 Inst Own81.50% Short Float- Perf Quarter-16.76%
Sales- P/S- EPS this Y-54.80% Inst Trans0.02% Short Ratio33.24 Perf Half Y-
Book/sh10.23 P/B1.58 EPS next Y64.70% ROA- Target Price26.40 Perf Year-
Cash/sh6.72 P/C2.41 EPS next 5Y- ROE- 52W Range11.23 - 23.99 Perf YTD0.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-32.51% Beta-
Dividend %- Quick Ratio25.30 Sales past 5Y- Gross Margin- 52W Low44.17% ATR0.95
Employees28 Current Ratio25.30 Sales Q/Q- Oper. Margin- RSI (14)44.42 Volatility4.97% 5.44%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.69 Prev Close16.00
ShortableYes LT Debt/Eq0.00 EarningsAug 12 BMO Payout- Avg Volume19.95K Price16.19
Recom1.50 SMA20-3.52% SMA50-4.65% SMA2002.35% Volume35,931 Change1.19%
Sep-10-21Initiated BofA Securities Buy $26
May-25-21Initiated SVB Leerink Outperform $29
May-25-21Initiated Jefferies Buy $22
May-25-21Initiated H.C. Wainwright Buy $32
May-25-21Initiated Evercore ISI Outperform $23
Sep-14-21 08:00AM  
Sep-08-21 08:00AM  
Aug-19-21 10:57AM  
Aug-18-21 07:30AM  
Aug-12-21 07:00AM  
Jul-30-21 05:03AM  
Jun-24-21 07:00AM  
Jun-18-21 09:16PM  
Jun-15-21 07:00AM  
Jun-10-21 07:00AM  
May-27-21 07:30AM  
May-21-21 07:41PM  
Apr-30-21 04:44PM  
Apr-29-21 09:19PM  
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorJun 16Buy13.379,285124,1404,291,881Jun 16 04:58 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 15Buy12.957,958103,0564,282,596Jun 16 04:58 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 14Buy12.75306,0553,902,2014,274,638Jun 16 04:58 PM
Sphera Global Healthcare Manag10% OwnerMay 04Buy16.00475,0007,600,000787,997May 04 01:21 PM
Longwood Fund III GP, LLC10% OwnerMay 04Buy16.00250,0004,000,0001,677,082May 04 04:30 PM
Arkin Bio Ventures 2 L.P.10% OwnerMay 04Buy16.00400,0006,400,0002,046,634May 04 04:31 PM
Asanuma SakaeDirectorMay 04Buy16.00312,5005,000,0002,068,909May 04 04:31 PM
Taiho Ventures LLC10% OwnerMay 04Buy16.00312,5005,000,0002,068,909May 04 04:31 PM
Lazarus AlonDirectorMay 04Buy16.00400,0006,400,0002,046,634May 04 04:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 04Buy16.001,715,00027,440,0003,524,758May 06 04:31 PM
MPM BioVentures 2014, L.P.10% OwnerMay 04Buy16.00125,7592,012,1443,187,998May 06 04:20 PM
GADICKE ANSBERT10% OwnerMay 04Buy16.00245,0003,920,0006,672,183May 06 04:19 PM
EVNIN LUKEDirectorMay 04Buy16.00150,7992,412,7844,284,172May 06 04:19 PM
Flynn James EPossible Member of 10% GroupMay 04Buy16.00800,00012,800,0002,552,787May 04 12:34 PM